REGENERON PHARMACEUTICALS, INC. Available-for-sale Securities, Amortized Cost Basis
REGENERON PHARMACEUTICALS, INC. (REGN) had Available-for-sale Securities, Amortized Cost Basis of $2.38 billion as of 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-05-03
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $2.38B.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $2.03B; Available-for-sale Securities, Amortized Cost Basis as first filed $2.08B.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $1.88B.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $1.59B.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2018-03-31 | $2.38B 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $2.03B 10-Q · filed 2018-05-03 | $2.08B 10-K · filed 2018-02-08 |
| 2017-09-30 | $1.88B 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $1.59B 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $1.47B 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $1.38B 10-K · filed 2018-02-08 | |
| 2016-09-30 | $1.27B 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $981.62M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $794.49M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $856.43M 10-K · filed 2017-02-09 | |
| 2015-09-30 | $911.85M 10-Q · filed 2015-11-04 | |
| 2015-03-31 | $643.94M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $631.48M 10-K · filed 2016-02-11 | |
| 2014-09-30 | $806.13M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $760.76M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $718.37M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $548.32M 10-K · filed 2015-02-12 | |
| 2013-03-31 | $483.14M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $354.99M 10-K · filed 2014-02-13 | |
| 2011-12-31 | $325.89M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |